Ergomed logo

ERGO - Ergomed News Story

788p 18.0  2.3%

Last Trade - 23/09/20

Mid Cap
Market Cap £372.8m
Enterprise Value £363.9m
Revenue £68.3m
Position in Universe 586th / 1807

Ergomed plc - Board appointment

Mon 2nd July, 2018 7:00am
RNS Number : 1615T
Ergomed plc
02 July 2018



Board appointment


Ergomed strengthens Management Team and Board with appointment of Stuart Jackson as Chief Financial Officer


London, UK - 2 July 2018: Ergomed plc, (LSE:ERGO) ("Ergomed" or the "Company")  a company focused on providing specialised services to the pharmaceutical industry, today announces a change to its Board and management team with the appointment of Stuart Jackson as Chief Financial Officer with immediate effect.


Stuart brings with him 20 years' experience at Chief Financial Officer level, having managed companies on the London, NASDAQ and Oslo Stock Exchanges. He has significant international experience in early stage and growth companies as well as managing significant and complex change projects. Stuart's experience has been gained primarily in the energy and technology/telecommunications sectors where consistent project service delivery across a number of geographies has been a key feature of business success.


He was Chief Financial Officer at Acergy SA responsible for the financial restructuring of the business and implementation of the new business strategy which took Acergy from $0.1bn to $6.0bn market capitalisation over a four year period. More recently he was Chief Financial Officer at CEONA, a Goldman Sachs Capital Partners group of companies, where he was responsible for the early stage set-up and growth of the business and Bibby Offshore Holdings Limited where, as Chief Financial Officer, he also managed the strategic development and M&A activities and oversaw its recent recapitalisation.


Stephen Stamp, Chief Executive Officer of Ergomed commented: "Stuart brings to Ergomed a strong track record of delivery within project and service related businesses on an international scale. His experience in non-healthcare services businesses will provide a broader perspective to our project delivery and he will play an integral role in enhancing the strong foundations of Ergomed as we seek to deliver our strategy of taking a market leading positon.  I very much look forward to working closely with Stuart in the next stage of our exciting development."


Peter George, Chairman of Ergomed commented: "I am very pleased to welcome Stuart to the Ergomed plc board. His expertise and experience across a broad range of businesses will be invaluable as we continue to grow our services and expand into new related areas."


Stuart holds a BSc in Accounting & Financial Management from Loughborough University of Technology and he is a Fellow of the Chartered Institute of Management Accountants. He has a beneficial holding of 1,845 ordinary shares in the Company.


Save as disclosed below, in relation to current and prior directorships, Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Stuart Jackson's appointment.


Mr Stuart Robert Jackson, aged 58, currently holds and has held the following directorships in the past five years:


Current directorships:

Amava Resorts Pty

Key Energy Finance Limited

Tortuga Energy Services Limited

Directorships in the past five years:

Bibby Offshore Holdings Limited

Bibby Offshore Services Plc

Bibby Subsea Inc.

Bibby Subsea Rov

Ceona Chartering (UK) Limited

Ceona Contracting (UK) Limited

Ceona Equipment Limited

Ceona Holding Ltd

Ceona Investments Limited

Ceona Pte. Ltd.

Ceona Services (UK) Limited

Ceona Ship 1 Limited

Ceona Ship 2 Limited

Ceona Ship 3 Limited

Ceona Ship Holdings Limited

Newco 987 Limited

Oig Giant I Pte. Ltd.

Oig Giant Ii Pte. Ltd.

Project Development International Limited

Tartaruga Limited


- Ends -




Ergomed plc

Tel: +44 (0) 1483 503 205

Stephen Stamp (Chief Executive Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Joint Broker)

N+1 Singer

Tel: +44 (0) 20 7496 3000

Aubrey Powell (Joint Broker)

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Olivia Manser

MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke


About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit:

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.